OneSource and Formycon ink manufacturing pactIllustrative image – not actual.

German biopharmaceutical company, Formycon and OneSource Specialty Pharma have announced a manufacturing partnership to support global biosimilar programmes.

Under the agreement, OneSource will act as a key manufacturing partner for Formycon, providing integrated drug substance (DS) and drug product (DP) manufacturing capabilities from its advanced biologics facility in Bangalore.. The collaboration combines Formycon’s expertise in biosimilar development and commercialisation with OneSource’s end-to-end biologics manufacturing capabilities to deliver scalable, high-quality solutions for international markets. Formycon brings a strong pipeline and established experience in developing biosimilar medicines, while OneSource contributes its integrated biologics platform covering cell line development, manufacturing and commercial fill-finish operations.

The companies said the collaboration reflects their shared commitment to advancing affordable and sustainable healthcare solutions by combining scientific innovation with robust manufacturing infrastructure.

 

← All latest storiesBack to top →